ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus

Phase 3

Completed

Conditions: Liver Transplantation

Interventions: Drug: FK506E (modified release tacrolimus)
Drug: Prograf (tacrolimus)

First Posted Date: 2009-05-28

Last Posted Date: 2010-04-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 10

Registration Number: NCT00909571

Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics

Completed

Conditions: Kidney Transplantation

Interventions: Other: Chart Review

First Posted Date: 2009-05-15

Last Posted Date: 2014-09-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 264

Registration Number: NCT00902980

A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Carcinoma, Pancreatic Ductal
Pancreatic Disease
Pancreatic Cancer

Interventions: Biological: Gemcitabine
Biological: AGS-1C4D4

First Posted Date: 2009-05-15

Last Posted Date: 2015-09-14

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 205

Registration Number: NCT00902291

Locations: 🇺🇸
University of California San Diego Medical Center, La Jolla, California, United States
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 32 locations

Reproducibility Study of Over Active Bladder Symptom Score [OABSS]

Completed

Conditions: Overactive Bladder

First Posted Date: 2009-05-13

Last Posted Date: 2011-03-15

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 50

Registration Number: NCT00901251

Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Phase 3

Completed

Conditions: Renal Dialysis
Renal Insufficiency
Hyperphosphatemia
Chronic Kidney Disease

Interventions: Drug: ASP1585

First Posted Date: 2009-05-04

Last Posted Date: 2015-05-04

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 248

Registration Number: NCT00892749

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Phase 1

Completed

Conditions: Solid Tumors
Ovarian Cancer

Interventions: Drug: OSI-906
Drug: Paclitaxel

First Posted Date: 2009-04-28

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 152

Registration Number: NCT00889382

Locations: 🇷🇴
Clinical Caunty Hospital Mures, Mures, Romania
🇨🇿
General University Hospital, Department of Obstetrics and Gynecology, Prague, Czechia
🇷🇴
Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala, Cluj Napoca, Romania

and more 43 locations

Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Tacrolimus
Drug: MMF
Drug: Corticosteroids (Prednisone)

First Posted Date: 2009-04-22

Last Posted Date: 2014-09-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 240

Registration Number: NCT00885820

Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers

Phase 1

Terminated

Conditions: Safety of ASP2151

Interventions: Drug: ASP2151
Drug: Valacyclovir
Drug: Placebo

First Posted Date: 2009-03-27

Last Posted Date: 2013-02-28

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 442

Registration Number: NCT00870441

An Open Study Assessing Bioavailability of a Modified Formulation of Tacrolimus in Kidney Transplant Recipients

Phase 3

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Tacrolimus, modified release

First Posted Date: 2009-03-19

Last Posted Date: 2014-07-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 27

Registration Number: NCT00865137

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

Phase 4

Completed

Conditions: Kidney Diseases
Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Regadenoson

First Posted Date: 2009-03-18

Last Posted Date: 2012-05-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 511

Registration Number: NCT00863707

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy